TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31515418
Drug: Corneal cross-linking
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corneal cross-linking (CXL) treatment
Study: 28766264
Drug: Acetaminophen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (20 mg/kg lean body mass)
Study: 20619242
Drug: Losartan (angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (angiotensin II receptor blocker)
Study: 17912637
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg daily for up to 5 years
Study: 17912637
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg daily for up to 5 years
Study: 12554545
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive therapy self-help program (n = 144)
Study: 9522144
Drug: Tramadol 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 0.6 mg kg‐1
Study: 9522144
Drug: Pethidine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine 0.6 mg kg‐1
Study: 9773840
Drug: Antenatal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal steroid administration
Study: 27246567
Drug: Varenicline (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (0, 1, 2 mg/d)
Study: 27246567
Drug: Varenicline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (1 and 2 mg/d)
Study: 27246567
Drug: High-dose alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose alcohol (0.08 g/dl)
Study: 18840370
Drug: Capsule formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule formulation of meclofenoxate hydrochloride 200 mg
Study: 18840370
Drug: Tablet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation of meclofenoxate hydrochloride 200 mg
Study: 12818406
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml of linseed oil (rich in ALA) per day (n=50)
Study: 12818406
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml of safflower oil (rich in LA) per day (n=26)
Study: 11933306
Drug: Radiant heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiant heat therapy
Study: 6240599
Drug: IK‐6‐Inhaletten (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IK‐6‐Inhaletten (0.1 mg Fenoterol + 0.04 mg Ipratropiumbromide)
Study: 6240599
Drug: SCH 1000‐Inhaletten
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 1000‐Inhaletten (0.2 mg Ipratropiumbromide)
Study: 27084301
Drug: Internet-based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based Cognitive Behavioral Therapy (CBT)
Study: 17573446
Drug: Roflumilast 500
Normalized name: ROFLUMILAST 500MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 500 microg once daily for 4 weeks
Study: 15670372
Drug: 5-fluorouracil-releasing microspheres
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil-releasing microspheres (130 mg) with early radiotherapy (59.4 Gy)
Study: 15670372
Drug: 5-fluorouracil-releasing microspheres
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil-releasing microspheres (130 mg) with early radiotherapy (59.4 Gy) in patients with complete resection
Study: 12191977
Drug: Warfarin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (target INR of 1.4 to 1.9)
Study: 29649425
Drug: 60 g freeze‐dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g freeze‐dried polyphenol‐rich whole grape powder (GP)
Study: 29649425
Drug: 4 weeks
Normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of daily GP consumption
Study: 28103829
Drug: Intravenous hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydration with three litres of Hartmann's solution between midnight and 8 am before kidney donation
Study: 28103829
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intravenous hydration)
Study: 29452204
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antiviral therapy)
Study: 26122235
Drug: Sustained virus
Normalized name: rubella virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained virus response to antiviral therapy
Study: 26122235
Drug: No response
Approvals — FDA: no, EMA: no, PMDA: no
Description: No response to antiviral therapy
Study: 23614999
Drug: BMS-663068 monotherapy
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-663068 monotherapy
Study: 21923713
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential therapy (pantoprazole 40 mg + amoxicillin 1000 mg twice a day for 5 days, then pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg twice a day for 5 days)
Study: 21923713
Drug: 14-day PPI-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day PPI-based triple therapy (pantoprazole 40 mg + amoxicillin 1000 mg + clarithromycin 500 mg twice a day for 14 days)
Study: 16400951
Drug: Qingkailing soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingkailing soft capsules (1.6 g, 4 times a day)
Study: 16400951
Drug: Qingkailing soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingkailing soft capsules
Study: 31855680
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (1.5 mg estradiol and 2.5 mg nomegestrolacetate)
Study: 8749600
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (COC)
Study: 23989087
Drug: MIXED hemodiafiltration
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIXED hemodiafiltration at Qb 250 ml/min
Study: 23989087
Drug: PRE hemodiafiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRE hemodiafiltration at Qb 250 ml/min
Study: 23989087
Drug: MIXED hemodiafiltration
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIXED hemodiafiltration at Qb 300 ml/min
Study: 23989087
Drug: PRE hemodiafiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRE hemodiafiltration at Qb 300 ml/min
Study: 19419350
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (HS) 4 ml/kg
Study: 19419350
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch (HES) 4 ml/kg
Study: 16765146
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CC genotype)
Study: 11688080
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement in the form of a fortified powder fruit drink, consumed 25 grams per school day for six months.
Study: 9264076
Drug: Alcohol (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.25, 0.5, or 1.0 g/kg)
Study: 8971287
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 800 mg
Study: 7888296
Drug: Ranitidine hydrochloride
Normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine hydrochloride 300 mg
Study: 9657539
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg o.d.)
Study: 3250317
Drug: Metoprolol CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR (100 mg o.d.)
Study: 23564211
Drug: Cetirizine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 15 mg + Verapamil 120 mg (P-gp blocker)
Study: 23564211
Drug: Cetirizine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 15 mg
Study: 9008458
Drug: Verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 120 mg
Study: 20224056
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose alteplase (0.90 ± 0.02 mg/kg)
Study: 20224056
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose alteplase (0.72 ± 0.07 mg/kg)
Study: 20224056
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose alteplase (0.90 ± 0.02 mg/kg) in patients ≥ 70 years old
Study: 20224056
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose alteplase (0.72 ± 0.07 mg/kg) in patients ≥ 70 years old
Study: 18359865
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate (400 mg to 1,200 mg) plus temozolomide (150-200 mg/m² per day on days 4-8)
Study: 18359865
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate (1,000 mg) plus temozolomide (150-200 mg/m² per day on days 4-8)
Study: 9777766
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% gel plus mid-potency corticosteroid cream
Study: 9777766
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% gel plus high-potency corticosteroid cream
Study: 9777766
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% gel plus placebo cream
Study: 7835452
Drug: Diclofenac and
Normalized name: diclofenac and antiinfectives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac and gentamicin combination
Study: 7835452
Drug: Betamethasone and
Normalized name: betamethasone and mydriatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone and neomycin combination
Study: 30904939
Drug: Metformin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (up to 1 g twice daily)
Study: 29693650
Drug: Phenylbutyrate (NaPB;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutyrate (NaPB; 7.15 g•m‐2BSA•day‐1)
Study: 29693650
Drug: Benzoate (NaBz;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzoate (NaBz; 5.5 g•m‐2BSA•day‐1)
Study: 29693650
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (MIX arm; 3.575 g NaPB and 2.75 g NaBz•m‐2BSA•day‐1)
Study: 29693650
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (MIX arm)
Study: 27620995
Drug: Oral simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral simvastatin 40 mg once daily for 3-7 days before surgery
Study: 27620995
Drug: Oral simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral simvastatin 40 mg
Study: 25080284
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of levodopa intake and subthalamic nucleus stimulation
Study: 22574592
Drug: Biqi Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biqi Capsule (BQC)
Study: 19604584
Drug: Integrated cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated cognitive behaviour therapy (CBT) treatment program, 10 sessions over 20 weeks.
Study: 15857738
Drug: Chemotherapy (FEM=5-FU,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (FEM=5-FU, epirubicin, and mitomycin C)
Study: 9392310
Drug: GST monitoring
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GST monitoring reported daily to the ward (reporting group)
Study: 3109602
Drug: 20% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% glucose solution with 6 g salt
Study: 3109602
Drug: Boiled macaroni
Normalized name: BOIL-EASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boiled macaroni with 6 g salt
Study: 3109602
Drug: 20% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% glucose solution without salt
Study: 31506074
Drug: Neuromuscular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular electrical stimulation (NMES) once daily for 20 minutes, electrical current increased up to 70 mA until contraction detected.
Study: 26686043
Drug: Eltrombopag (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (50 mg to 300 mg daily)
Study: 23485887
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low protein diet (VLPD; 0.3 g/kg bw/day)
Study: 23485887
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet (LPD; 0.6 g/kg bw/day)
Study: 21599433
Drug: Deferiprone 75
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone 75 mg/kg 4 days/week and DFO 50 mg/kg/day for 3 days/week
Study: 21599433
Drug: Deferiprone alone
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone alone 75 mg/kg 7 days/week
Study: 19439117
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (target group, blood glucose 6.2 to 8.3 mmol/L)
Study: 19439117
Drug: Routine insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine insulin therapy (routine group, blood glucose 4.1 to 6.1 mmol/L)
Study: 17012299
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day rosuvastatin therapy
Study: 12455724
Drug: Antioxidant treatment
Normalized name: OCTINOXATE 6 g in 100 g / AVOBENZONE 1.7 g in 100 g TOPICAL CREAM [Renewing Antioxidant Treatment SPF 6 GNLD International]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant treatment
Study: 29927398
Drug: Cytoflavin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin (2 tablets 2 times a day)
Study: 29927398
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy (Control)
Study: 25077847
Drug: Non-MBCT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-MBCT group therapy
Study: 22284022
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with varying levels of depressive symptoms (NO, SLOW, GO)
Study: 22049891
Drug: Gargling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gargling with ketamine 50 mg in drinking water 30 ml for 30 s, 5 min before induction of anaesthesia
Study: 22049891
Drug: Gargling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gargling with drinking water 30 ml
Study: 15753530
Drug: Zinc supplement
Normalized name: Zinc supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplement of 25 mg daily for 14 days
Study: 10569419
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 500 mg BID for 3-8 days preoperatively
Study: 10569419
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 500 mg BID for 9-14 days preoperatively
Study: 6349560
Drug: Combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined group A and group C meningococcal polysaccharide vaccine
Study: 30855463
Drug: Sufentanil 0.2
Normalized name: ropivacaine-sufentanil 0.2%-1 mcg/mL-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.2 μg/kg
Study: 31820593
Drug: Sufentanil 0.1
Normalized name: bupivacaine-sufentanil 0.1%-1 mcg/mL-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.1 μg/kg
Study: 30855463
Drug: Sufentanil 0.05
Normalized name: sufentanil 0.05 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.05 μg/kg
Study: 30855463
Drug: Sufentanil 0
Normalized name: SUFentanil 0.03 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0 μg/kg (control group)
Study: 30855463
Drug: Sufentanil 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.15 μg/kg
Study: 24314857
Drug: Warm saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm saline mouth rinse six times daily (Group A)
Study: 24314857
Drug: Warm saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm saline mouth rinse twice daily (Group B)
Study: 19308417
Drug: Interferon beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1a (treatment initiation)
Study: 17279280
Drug: Nutritional guidance
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional guidance in the first year of life with monthly follow‐up home visits
Study: 9852628
Drug: Germinated barley
Approvals — FDA: no, EMA: no, PMDA: no
Description: Germinated barley foodstuff (GBF) 30 g/day for 28 days
Study: 2465457
Drug: Aprotinin (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (700 mg approximately)
Study: 27911869
Drug: TOF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOF regimen (paclitaxel 135 mg/m2 iv on day 1, oxaliplatin 100 mg/m2 iv on day 1, fluorouracil 500 mg/m2 continuous iv on day 1-5)
Study: 27911869
Drug: SOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOX regimen (oxaliplatin 130 mg/m2 iv on day 1, S-1 40 mg/60mg orally twice/day on days 1-14)
Study: 21300736
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon beta‐1a (IFNβ‐1a) treatment
Study: 16864757
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg of recombinant human thyrotropin
Study: 8791047
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of neo‐adjuvant treatment with triptorelin (3.75 mg i.m. every 28 days) and cyproterone acetate (50 mg b.i.d. for 3 weeks)
Study: 1781051
Drug: Ibuprofen (Ibumetin)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (Ibumetin)
Study: 1455326
Drug: Paracetamol/codeine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol/codeine combination (Citodon)
Study: 28881347
Drug: Curcumin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin supplementation (500 mg capsules, 2 capsules daily for 12 weeks)
Study: 28881347
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 placebo capsules daily for 12 weeks)
Study: 26216378
Drug: Nebulized fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized fluticasone propionate (2000 mcg/day)
Study: 16685542
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (1 mg/kg/day)
Study: 16562650
Drug: Adjuvant radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiation therapy combined with chemotherapy
Study: 12706932
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated estrogen (CEE) (0.625 mg/day)
Study: 12706932
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (E(2)) (100 microg/day)
Study: 10675209
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for TBM, duration not specified
Study: 9586515
Drug: Michigan splint
Normalized name: influenza B virus B/Michigan/01/2021 antigen
DrugBank: Influenza B virus B/Michigan/01/2021 antigen (formaldehyde inactivated) (DB16917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Michigan splint therapy for two months
Study: 23059922
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no active treatment)
Study: 8246258
Drug: E. coli
Normalized name: E. coli antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: E. coli O157 agglutinating antibodies
Study: 8246258
Drug: IgG antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibodies against whole intact E. coli O157 cells
Study: 3542383
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy for breast cancer
Study: 27354079
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm with time-controlled, manualised wellness rehabilitation consultation focused on healthy nutrition and exercise post-chemotherapy.
Study: 23468100
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of alcohol, clamped at a steady-state breath alcohol (BrAC) concentration of 60 mg/dL
Study: 31928949
Drug: Placebo saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo saline infusion
Study: 16585985
Drug: Topical methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical methyl aminolevulinate photodynamic therapy (160 mg/g cream applied for 3 h prior to illumination by non‐coherent red light at 570‐670 nm, light dose 75 J/cm2)
Study: 16585985
Drug: Topical methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical methyl aminolevulinate photodynamic therapy
Study: 12669898
Drug: Daily ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ASA treatment after ASA desensitization
Study: 1303336
Drug: Ivermectin 0.1
Normalized name: ivermectin 0.136 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin 0.1 mg/kg orally at a single dose
Study: 1303336
Drug: Ivermectin 0.2
Normalized name: ivermectin 0.272 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin 0.2 mg/kg orally at a single dose